<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Eur Acad Dermatol Venereol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Eur Acad Dermatol Venereol</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1468-3083</journal-id>
      <journal-id journal-id-type="publisher-id">JDV</journal-id>
      <journal-title-group>
        <journal-title>Journal of the European Academy of Dermatology and Venereology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0926-9959</issn>
      <issn pub-type="epub">1468-3083</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25688670</article-id>
      <article-id pub-id-type="pmc">4973684</article-id>
      <article-id pub-id-type="doi">10.1111/jdv.13034</article-id>
      <article-id pub-id-type="publisher-id">JDV13034</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Short Report</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Original Articles and Short Reports</subject>
          <subj-group subj-group-type="heading">
            <subject>Genodermtoses</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A novel mutation in <styled-content style="fixed-case">IL</styled-content>36<styled-content style="fixed-case">RN</styled-content> underpins childhood pustular dermatosis</article-title>
        <alt-title alt-title-type="left-running-head">Ellingford <italic>et&#xA0;al</italic>.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="jdv13034-cr-0001" contrib-type="author">
          <name>
            <surname>Ellingford</surname>
            <given-names>J.M.</given-names>
          </name>
          <xref ref-type="aff" rid="jdv13034-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jdv13034-cr-0002" contrib-type="author">
          <name>
            <surname>Black</surname>
            <given-names>G.C.M.</given-names>
          </name>
          <xref ref-type="aff" rid="jdv13034-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jdv13034-cr-0003" contrib-type="author">
          <name>
            <surname>Clayton</surname>
            <given-names>T.H.</given-names>
          </name>
          <xref ref-type="aff" rid="jdv13034-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="jdv13034-cr-0004" contrib-type="author">
          <name>
            <surname>Judge</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="jdv13034-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="jdv13034-cr-0005" contrib-type="author">
          <name>
            <surname>Griffiths</surname>
            <given-names>C.E.M.</given-names>
          </name>
          <xref ref-type="aff" rid="jdv13034-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="jdv13034-cr-0006" contrib-type="author" corresp="yes">
          <name>
            <surname>Warren</surname>
            <given-names>R.B.</given-names>
          </name>
          <xref ref-type="aff" rid="jdv13034-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="jdv13034-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Manchester Centre for Genomic Medicine</named-content>
        <institution>Central Manchester University Hospitals NHS Foundation Trust</institution>
        <institution>Manchester Academic Health Science Centre</institution>
        <named-content content-type="city">Manchester</named-content>
        <country country="GB">UK</country>
      </aff>
      <aff id="jdv13034-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">The Dermatology Centre</named-content>
        <institution>Salford Royal NHS Foundation Trust</institution>
        <institution>Manchester Academic Health Science Centre</institution>
        <institution>University of Manchester</institution>
        <named-content content-type="city">Manchester</named-content>
        <country country="GB">UK</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>Correspondence: R.B. Warren. E&#x2010;mail: <email>richard.warren@manchester.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>2</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <volume>30</volume>
      <issue>2</issue>
      <issue-id pub-id-type="doi">10.1111/jdv.2016.30.issue-2</issue-id>
      <fpage>302</fpage>
      <lpage>305</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 European Academy of Dermatology and Venereology <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2015 The Authors. <italic>Journal of the European Academy of Dermatology and Venereology</italic> published by John Wiley &amp; Sons Ltd on behalf of European Academy of Dermatology and Venereology.</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDV-30-302.pdf"/>
      <abstract id="jdv13034-abs-0001">
        <title>Abstract</title>
        <sec id="jdv13034-sec-0001">
          <title>Background</title>
          <p>Chronic pustular dermatoses are severe and debilitating autoinflammatory conditions that can have a monogenic basis. Their clinical features are, however, complex with considerable overlap. Null and missense mutations in the genes encoding interleukin (<styled-content style="fixed-case">IL</styled-content>)&#x2010;1 family (<styled-content style="fixed-case">IL</styled-content>&#x2010;1 and <styled-content style="fixed-case">IL</styled-content>&#x2010;36) anti&#x2010;inflammatory receptor antagonist (Ra) cytokines can underlie the development of severe pustular dermatoses.</p>
        </sec>
        <sec id="jdv13034-sec-0002">
          <title>Objective</title>
          <p>We present a clinical and genetic study of four children of Pakistani descent with similar clinical presentations and treatment course, each of whom suffers from a severe pustular dermatosis, initially described as a pustular variant of psoriasis. We use <styled-content style="fixed-case">DNA</styled-content> sequencing to refine the diagnosis of two of the children studied.</p>
        </sec>
        <sec id="jdv13034-sec-0003">
          <title>Methods</title>
          <p>Bidirectional Sanger sequencing was performed on the coding regions of the <styled-content style="fixed-case">IL</styled-content>&#x2010;1Ra and <styled-content style="fixed-case">IL</styled-content>&#x2010;36Ra genes (<italic><styled-content style="fixed-case">IL</styled-content>1<styled-content style="fixed-case">RN</styled-content></italic> and <italic><styled-content style="fixed-case">IL</styled-content>36<styled-content style="fixed-case">RN</styled-content></italic>, respectively), for the four affected children and their parents.</p>
        </sec>
        <sec id="jdv13034-sec-0004">
          <title>Results</title>
          <p>We identified a novel homozygous missense mutation in <italic><styled-content style="fixed-case">IL</styled-content>36<styled-content style="fixed-case">RN</styled-content></italic> in two siblings, and showed the molecular basis of the condition to be both distinct from psoriasis and distinct between the two families studied.</p>
        </sec>
        <sec id="jdv13034-sec-0005">
          <title>Conclusions</title>
          <p>We describe a novel mutation which underpins the diagnosis of childhood pustular dermatosis. Molecular diagnostics can be used to aid the clinical diagnosis and potential treatment of autoinflammatory conditions.</p>
        </sec>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>BSF</funding-source>
          <award-id>S820</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>MRC Training</funding-source>
          <award-id>MR/J016004/1</award-id>
        </award-group>
      </funding-group>
      <counts>
        <page-count count="4"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>jdv13034</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>February 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:04.08.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <fn-group id="jdv13034-ntgp-0001">
        <fn id="jdv13034-note-0001">
          <p>
<bold>Conflict of interest</bold>
</p>
          <p>None declared.</p>
        </fn>
        <fn id="jdv13034-note-0002">
          <p>
<bold>Funding sources</bold>
</p>
          <p>BSF grant, S820; MRC Training grant, MR/J016004/1.</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <sec id="jdv13034-sec-0006">
      <title>Introduction</title>
      <p>Autoinflammatory conditions are a group of genetic diseases,&#xA0;characterized by&#xA0;an&#xA0;innate immune&#xA0;response to&#xA0;endogenous cells,&#xA0;which can impact significantly on&#xA0;health and quality of life. The exact pathogenesis of autoinflammatory conditions is&#xA0;difficult to&#xA0;determine&#xA0;from their clinical phenotypes, which are frequently complex with overlapping&#xA0;features.<xref rid="jdv13034-bib-0001" ref-type="ref">1</xref> The accurate identification of genetic&#xA0;mutations that&#xA0;underpin autoinflammatory conditions can help to determine their pathogenesis and&#xA0;thereby&#xA0;assist in determining the most appropriate treatment option.<xref rid="jdv13034-bib-0002" ref-type="ref">2</xref>
</p>
    </sec>
    <sec id="jdv13034-sec-0007">
      <title>Clinical presentation</title>
      <sec id="jdv13034-sec-0008">
        <title>Family 1</title>
        <p>An 18&#x2010;month&#x2010;old girl born to consanguineous Pakistani parents presented with a rapid onset of fever and systemic upset. Clinical examination revealed generalised erythema studded with follicular pustules concentrated mainly on the infant's limbs and trunk (Fig.&#xA0;<xref rid="jdv13034-fig-0001" ref-type="fig">1</xref>a, II.1a). She had no pre&#x2010;existing skin condition. The sudden appearance of inflamed pustules and fever concurrent with clarithromycin use for an upper respiratory tract infection, suggested an initial diagnosis of acute generalised exanthematous pustulosis (<italic>AGEP</italic>; Table&#xA0;<xref rid="jdv13034-tbl-0001" ref-type="table-wrap">1</xref>). Withdrawal of clarithromycin and the use of non&#x2010;steroidal topical treatment reduced the inflammation, supporting the initial diagnosis of AGEP. However, she presented with identical clinical features 12&#xA0;months later (Fig.&#xA0;<xref rid="jdv13034-fig-0001" ref-type="fig">1</xref>a, II.1b), this time in the absence of a potential exogenous cause. The diagnosis was reassigned to generalised pustular psoriasis (Table&#xA0;<xref rid="jdv13034-tbl-0001" ref-type="table-wrap">1</xref>). Her 7&#x2010;year&#x2010;old brother also presented with a febrile illness, generalised erythema and pustules 2&#xA0;months after her second episode of inflamed pustules. He was not receiving medication and had pre&#x2010;existing plaques of erythema and scaling on his limbs and chest. Skin biopsies from both children were consistent with a diagnosis of pustular psoriasis. Topical application of calcipotriol proved ineffective for both children. Systemic treatment with acitretin, 10&#xA0;mg daily, for 6&#xA0;months relieved the febrile symptoms and pustule formation of both siblings. The addition of methotrexate (5&#xA0;mg for the girl, 7.5&#xA0;mg for the boy), once a week, in combination with acitretin after the initial 6&#x2010;month period has improved the condition of both children.</p>
        <table-wrap id="jdv13034-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>Disease characteristics</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">
<bold>1. Generalised Pustular Psoriasis (GPP)</bold>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
<italic>Typical presentation</italic>: Rapid development of widespread sterile pustules. Often associated with fever and fatigueMay have history of more typical Plaque Psoriasis. May be recurrent<italic>Molecular basis</italic>: Heterogeneous<italic>Stimulus for presentation</italic>: Mostly unknown, but may present in response to infection or withdrawal of steroid therapy<bold>2. Acute generalised Exanthematous Pustulosis (AGEP)</bold>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
<italic>Typical presentation</italic>: Rapid development of widespread sterile pustules. Rarely associated with fever and systemic illness<italic>Molecular basis</italic>: Heterogeneous<italic>Stimulus for presentation</italic>: Most commonly exogenous agent use, e.g. antibiotics. Symptoms usually resolve within weeks of removal of causative stimulus<bold>3. Deficiency of Interleukin&#x2010;36 Receptor Antagonist Disorder (DITRA)</bold>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">
<italic>Typical presentation</italic>: Rapid development of widespread sterile pustules. Often associated with fever and fatigue<italic>Molecular basis</italic>: Mutations in <italic>IL36RN</italic>, which encodes the interleukin&#x2010;36 receptor antagonist cytokine<italic>Stimulus for presentation</italic>: Mostly unknown</td>
              </tr>
            </tbody>
          </table>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <fig fig-type="Figure" xml:lang="en" id="jdv13034-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Family pedigrees and clinical photographs of affected children. (a) Family 1, with <styled-content style="fixed-case">IL</styled-content>36<styled-content style="fixed-case">RN</styled-content> mutation profile (<italic><styled-content style="fixed-case">WT</styled-content></italic>, leucine amino acid; <italic>&#x2010;</italic>, proline amino acid), pictures show the girl's pustular dermatosis at age: 18&#xA0;months (<styled-content style="fixed-case">II</styled-content>.1a) and 2.5&#xA0;years (<styled-content style="fixed-case">II</styled-content>.1b). (b) Family 2, two elder daughters affected by pustular psoriasis.</p>
          </caption>
          <graphic id="nlm-graphic-1" xlink:href="JDV-30-302-g001"/>
        </fig>
      </sec>
      <sec id="jdv13034-sec-0009">
        <title>Family 2</title>
        <p>The first&#x2010;born daughter of a consanguineous Pakistani couple developed an eczematous rash in the flexures and groin at 2&#xA0;months of age. The rash recurred at 12&#xA0;months and the girl presented at 18&#xA0;months of age with exfoliative erythroderma and sparse hair. She was treated with topical steroids and oral flucloxacillin. She was lost to follow&#x2010;up, during which time she received oral prednisolone. She returned aged&#xA0;23&#xA0;months with fever, exfoliative erythroderma, palmoplantar pustules&#xA0;and Cushingoid features. During her recovery, psoriasiform lesions were noted on her lower back (Fig.&#xA0;<xref rid="jdv13034-fig-0001" ref-type="fig">1</xref>b, II.1); Netherton's syndrome was excluded on skin biopsy, which showed normal Lympho&#x2010;Epithelial Kazal&#x2010;Type&#x2010;related Inhibitor (LEKTI) staining and features consistent with psoriasis. Over the ensuing 5&#xA0;years she had recurrent eruptions of widespread migratory pustular psoriasis with fever and transient nail dystrophy, on a background of persistent flexural, vulval and generalised plaque psoriasis. Plaque and pustular lesions involved ~50% body surface area during her worst flares, necessitating several hospital admissions. Daily treatment with 10&#xA0;mg acitretin was started at age 7&#xA0;years. Her condition rapidly improved and although she has had several minor flares of plaque and pustular psoriasis since, she has not required admission and, aged 10&#xA0;years, reports a good quality of life.</p>
        <p>Her younger sister, now aged 6&#xA0;years, followed a very similar disease course, developing severe exfoliative erythroderma with palmoplantar pustulosis aged&#xA0;2&#xA0;months (Fig.&#xA0;<xref rid="jdv13034-fig-0001" ref-type="fig">1</xref>b, II.2), and progressing to frequent bouts of pustular psoriasis with systemic features and transient nail dystrophy. She has had scattered mild plaque psoriasis and improved significantly after daily treatment with 10&#xA0;mg acitretin at age 3.5&#xA0;years.</p>
        <p>A third child, a daughter, was born in 2013. She has Down syndrome and, now at 18&#xA0;months of age, has not shown any sign of skin disease.</p>
      </sec>
    </sec>
    <sec id="jdv13034-sec-0010">
      <title>Genetics</title>
      <p>interleukin (IL)&#x2010;1 superfamily contains 11 molecules that play a pivotal role in innate immunity, including proinflammatory cytokines IL&#x2010;1 (&#x3B1; and &#x3B2;) and IL&#x2010;36 (&#x3B1;, &#x3B2; and &#x3B3;), and anti&#x2010;inflammatory receptor antagonist (Ra) cytokines IL&#x2010;1Ra and IL&#x2010;36Ra.<xref rid="jdv13034-bib-0003" ref-type="ref">3</xref> Recently, genetics research has facilitated the sub&#x2010;classification of autoinflammatory pustular disorders caused by mutations in genes within the IL&#x2010;1 superfamily.<xref rid="jdv13034-bib-0004" ref-type="ref">4</xref>
</p>
      <p>Interleukin&#x2010;1Ra and IL&#x2010;36Ra are anti&#x2010;inflammatory cytokines that bind to the IL&#x2010;1 and IL&#x2010;36 cell membrane receptors, respectively, without initiating a downstream inflammatory response.<xref rid="jdv13034-bib-0003" ref-type="ref">3</xref>, <xref rid="jdv13034-bib-0005" ref-type="ref">5</xref> Interleukin&#x2010;1Ra and IL&#x2010;36Ra inhibit the binding of IL&#x2010;1 family proinflammatory cytokines to their membrane receptors, and hence act as inhibitors of IL&#x2010;1 and IL&#x2010;36 cytokine mediated inflammation. Recessively inherited null and missense mutations in the genes encoding IL&#x2010;1Ra (<italic>IL1RN</italic>) and IL&#x2010;36Ra (<italic>IL36RN</italic>) can cause the development of severe pustular dermatoses,<xref rid="jdv13034-bib-0003" ref-type="ref">3</xref>, <xref rid="jdv13034-bib-0005" ref-type="ref">5</xref>, <xref rid="jdv13034-bib-0006" ref-type="ref">6</xref>, <xref rid="jdv13034-bib-0007" ref-type="ref">7</xref> and are now recognized as discrete clinical diagnoses: deficiency of IL&#x2010;36Ra disorder (DITRA)<xref rid="jdv13034-bib-0003" ref-type="ref">3</xref>; and deficiency of IL&#x2010;1Ra disorder (DIRA).<xref rid="jdv13034-bib-0005" ref-type="ref">5</xref>
</p>
      <p>In this study, polymerase chain reaction and bidirectional Sanger sequencing were performed on DNA extracted from peripheral blood samples of the affected children and their consanguineous parents, to acquire a mutation profile of all known coding exons of <italic>IL36RN</italic> and <italic>IL1RN</italic>. A novel homozygous missense variant in <italic>IL36RN,</italic> c.62T&gt;C p.Leu21Pro (NM_173170.1), present in an exon containing other disease&#x2010;causing mutations<xref rid="jdv13034-bib-0003" ref-type="ref">3</xref> was found in both affected children of the first family, with a heterozygous genotype in their unaffected parents (Figs&#xA0;<xref rid="jdv13034-fig-0001" ref-type="fig">1</xref>a and <xref rid="jdv13034-fig-0002" ref-type="fig">2</xref>). No other homozygous or <italic>de novo</italic> variant was found exclusively in the affected children of the first family. Comparison with the 1000 genomes, Exome Variant Server and dbSNP databases identified that the c.62T&gt;C variant has not been reported previously. <italic>IL36RN</italic> c.62T&gt;C is also absent from the Manchester Centre for Genomic Medicine in&#x2010;house database, which contains whole&#x2010;exome sequencing data for more than 500 patients, of which ~25% are of Asian descent. Condel <italic>in&#x2010;silico</italic> prediction software<xref rid="jdv13034-bib-0008" ref-type="ref">8</xref> provides a consensus score for popular missense prediction algorithms; Condel indicated that the p.Leu21Pro variant would have a deleterious impact on the structure of the <italic>IL36RN</italic> protein. The predicted disruption of the structure, and therefore function, of IL&#x2010;36Ra is consistent with the observed febrile illness and widespread pustular lesions in two of the four children reported in this study.<xref rid="jdv13034-bib-0003" ref-type="ref">3</xref>
</p>
      <fig fig-type="Figure" xml:lang="en" id="jdv13034-fig-0002" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Staden display of <italic><styled-content style="fixed-case">IL</styled-content>36<styled-content style="fixed-case">RN</styled-content></italic> sanger sequencing results from Family 1. [vertical line shows <styled-content style="fixed-case">cDNA</styled-content> position 62 at codon 21 in the <italic><styled-content style="fixed-case">NM</styled-content>_173170.1</italic> transcript]. (a) control <styled-content style="fixed-case">DNA</styled-content> with a homozygous T/T genotype. (b) example of parent <styled-content style="fixed-case">DNA</styled-content> with T/C heterozygous genotype. (c) example of affected child <styled-content style="fixed-case">DNA</styled-content> with C/C homozygous genotype.</p>
        </caption>
        <graphic id="nlm-graphic-3" xlink:href="JDV-30-302-g002"/>
      </fig>
      <p>In the absence of functional evidence, we cautiously define the <italic>IL36RN</italic> c.62T&gt;C p.Leu21Pro variant as a &#x2018;likely pathogenic&#x2019; mutation, and suggest the diagnosis in family 1 be redefined to DITRA.<xref rid="jdv13034-bib-0003" ref-type="ref">3</xref> c.62T&gt;C adds to an emerging array of mutations in <italic>IL36RN</italic> underpinning autoinflammatory disorders,<xref rid="jdv13034-bib-0007" ref-type="ref">7</xref> and has implications for future treatment options for patients reported with this mutation.<xref rid="jdv13034-bib-0002" ref-type="ref">2</xref> Initial evidence suggests that anakinra (Kineret<sup>&#xAE;</sup>, Sobi, Inc, Waltham, MA, USA), a human recombinant IL&#x2010;1Ra, can be used to treat paediatric pustular dermatoses caused by mutations in <italic>IL36RN</italic>.<xref rid="jdv13034-bib-0009" ref-type="ref">9</xref> Thus, transition of the children in the first family reported here to anakinra might be appropriate if their disease flares in the future. The monogenic nature of DITRA also has informed the genetic counselling that the family will receive, and will allow accurate and comprehensive parent education about the risk of additional offspring developing the disorder.</p>
      <p>In contrast, homozygous or <italic>de novo</italic> mutations in <italic>IL1RN</italic> or <italic>IL36RN</italic> were not found in the affected children of the second family. The lack of mutation in these individuals indicates that despite the increasing resolution with which genetic technology can define autoinflammatory disease, complex heterogeneity remains a significant difficulty for the diagnosis of patients with overlapping clinical features.</p>
      <p>In conclusion, genetic analysis of four Pakistani children suffering from pustular dermatoses uncovered a novel mutation in the IL&#x2010;1 family receptor antagonist gene <italic>IL36RN</italic>. The key benefits of understanding the molecular basis of the pustular dermatoses described here are an accurate assessment of: (i) the initial clinical diagnosis; (ii) the likelihood that additional offspring will inherit the disorder; and (iii) the most appropriate targeted therapy.</p>
    </sec>
  </body>
  <back>
    <ack id="jdv13034-sec-0011">
      <title>Acknowledgements</title>
      <p>CEMG is a National Institute of Health Research (NIHR) Senior Investigator and RBW is an NIHR Clinical Senior Lecturer.</p>
    </ack>
    <ref-list content-type="cited-references" id="jdv13034-bibl-0001">
      <title>References</title>
      <ref id="jdv13034-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0001">
<string-name>
<surname>Naik</surname>
<given-names>HB</given-names>
</string-name>, <string-name>
<surname>Cowen</surname>
<given-names>EW</given-names>
</string-name>. <article-title>Autoinflammatory pustular neutrophilic diseases</article-title>. <source>Dermatol Clin</source>
<year>2013</year>; <volume>31</volume>: <fpage>405</fpage>&#x2013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">23827244</pub-id></mixed-citation>
      </ref>
      <ref id="jdv13034-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0002">
<string-name>
<surname>Doherty</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Brydges</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Hoffman</surname>
<given-names>HM</given-names>
</string-name>. <article-title>Autoinflammation: translating mechanism to therapy</article-title>. <source>J Leuk Biol</source>
<year>2011</year>; <volume>90</volume>: <fpage>37</fpage>&#x2013;<lpage>47</lpage>.</mixed-citation>
      </ref>
      <ref id="jdv13034-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0003">
<string-name>
<surname>Marrakchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Guigue</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Renshaw</surname>
<given-names>BR</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>Interleukin&#x2010;36&#x2010;receptor antagonist deficiency and generalised pustular psoriasis</article-title>. <source>N Engl J Med</source>
<year>2011</year>; <volume>365</volume>: <fpage>620</fpage>&#x2013;<lpage>628</lpage>.<pub-id pub-id-type="pmid">21848462</pub-id></mixed-citation>
      </ref>
      <ref id="jdv13034-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0004">
<string-name>
<surname>Aksentijevich</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kastner</surname>
<given-names>DL</given-names>
</string-name>. <article-title>Genetics of monogenic autoinflammatory diseases: past successes, future challenges</article-title>. <source>Nat Rev Rheumatol</source>
<year>2011</year>; <volume>7</volume>: <fpage>468</fpage>&#x2013;<lpage>477</lpage>.</mixed-citation>
      </ref>
      <ref id="jdv13034-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0005">
<string-name>
<surname>Aksentijevich</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Masters</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Ferguson</surname>
<given-names>PJ</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>An autoinflammatory disease with deficiency of the interleukin&#x2010;1&#x2010;receptor antagonist</article-title>. <source>N Engl J Med</source>
<year>2009</year>; <volume>360</volume>: <fpage>2426</fpage>&#x2013;<lpage>2437</lpage>.<pub-id pub-id-type="pmid">19494218</pub-id></mixed-citation>
      </ref>
      <ref id="jdv13034-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0006">
<string-name>
<surname>Onoufriadis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Pink</surname>
<given-names>AE</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalised pustular psoriasis</article-title>. <source>Am J Hum Genet</source>
<year>2011</year>; <volume>89</volume>: <fpage>432</fpage>&#x2013;<lpage>437</lpage>.<pub-id pub-id-type="pmid">21839423</pub-id></mixed-citation>
      </ref>
      <ref id="jdv13034-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0007">
<string-name>
<surname>Setta&#x2010;Kaffetzi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Navarini</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>VM</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis&#x2010;associated pustular phenotypes</article-title>. <source>J Invest Dermatol</source>
<year>2013</year>; <volume>133</volume>: <fpage>1366</fpage>&#x2013;<lpage>1369</lpage>.<pub-id pub-id-type="pmid">23303454</pub-id></mixed-citation>
      </ref>
      <ref id="jdv13034-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0008">
<string-name>
<surname>Gonzalez&#x2010;Perez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lopez&#x2010;Bigas</surname>
<given-names>N</given-names>
</string-name>. <article-title>Improving the assessment of the outcome of nonsynonymous SNVs with a Consensus Deleteriousness Score, Condel</article-title>. <source>Am J Hum Genet</source>
<year>2011</year>; <volume>88</volume>: <fpage>440</fpage>&#x2013;<lpage>449</lpage>.<pub-id pub-id-type="pmid">21457909</pub-id></mixed-citation>
      </ref>
      <ref id="jdv13034-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="jdv13034-cit-0009">
<string-name>
<surname>Rossi&#x2010;Semerano</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Piram</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chiaverini</surname>
<given-names>C</given-names>
</string-name>
<italic>et&#xA0;al</italic>
<article-title>First clinical description of an infant with interleukin&#x2010;36&#x2010;receptor antagonist deficiency successfully treated with Anakinra</article-title>. <source>Pediatrics</source>
<year>2013</year>; <volume>132</volume>: <fpage>E1043</fpage>&#x2013;<lpage>E1047</lpage>.<pub-id pub-id-type="pmid">24019411</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
